Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-06

Clinical Trial Update: Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Avelumab in recurrent or metastatic nasopharyngeal cancer was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)

Snippet

Sponsor: Assuntina Sacco, M.D. | Conditions: Nasopharyngeal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-09-06